Drug intelligence / Profile preview

MSK-TCR5

Development stage: Phase 1
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MSK-TCR5 is an autologous, genetically engineered T-cell receptor (TCR) therapy developed by Memorial Sloan Kettering Cancer Center. It is designed to target the RAS G12D mutation (found in KRAS, HRAS, and NRAS genes) when presented by the HLA-A*11:01 human leukocyte antigen. The therapy is armored with CD8 alpha and beta chains to enhance the potency and persistence of the engineered T cells within the immunosuppressive tumor microenvironment. It is currently being evaluated in the Phase I FORTRAS clinical trial for patients with advanced solid tumors harboring the RAS G12D mutation.

Other names: CD8 Alpha/Beta Armored RAS G12D/HLA-A*11:01-specific T-cell Receptor Therapy

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on MSK-TCR5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSK-TCR5.

Explore the full profile